Explore
Upload

DocSlides is a free service to upload presentations and documents.

Upload Now

Search Results for 'Tdf Study'

Tdf Study published presentations and documents on DocSlides.

Joel E. Gallant, MD, MPH

Joel E. Gallant, MD, MPH

  • mastervisa
  • 11 Slides

Medical Director, Specialty . Services. Southwest ...

Evolving Options for HBV Therapy:

Evolving Options for HBV Therapy:

  • desiron
  • 39 Slides

Navigating the New Treatment Landscape. Outline. I...

Comparison of RTV vs Cobi

Comparison of RTV vs Cobi

  • studmonkeybikers
  • 11 Slides

GS-US-216-0114. . Gallant JE. JID 2013;208:32-9...

WHO ARV Forecasting Meeting

WHO ARV Forecasting Meeting

  • sistertive
  • 31 Slides

Geneva, March 19 - 20 , 2015 1 | Treatment and C...

937401234123534671341849346744x 19 333133Webinar Requirements A c

937401234123534671341849346744x 19 333133Webinar Requirements A c

  • erica
  • 72 Slides

HBcAbThis prescribe ARTART Dispensed0-5-14 Days0-1...

Selecting an Initial Antiretroviral Therapy (ART) Regimen

Selecting an Initial Antiretroviral Therapy (ART) Regimen

  • cappi
  • 30 Slides

www.hivguidelines.org. Purpose of . This Guideline...

Target Date Funds and P

Target Date Funds and P

  • unita
  • 12 Slides

lan . S. ponsor Responsibilities. Marcia S. Wagner...

Renal and Bone Safety of

Renal and Bone Safety of

  • ashley
  • 16 Slides

Tenofovir. . Alafenamide. . vs. . Tenofovir. ....

Eric S. Daar , MD Michael S.

Eric S. Daar , MD Michael S.

  • ButterflyHeart
  • 41 Slides

Saag. , MD. Antiretroviral Therapy:. A Case-Based ...

Total Soluble and Insoluble Dietary Fibre Contents of Wild Growing E

Total Soluble and Insoluble Dietary Fibre Contents of Wild Growing E

  • alyssa
  • 7 Slides

302 Vol. 32, 2014, No. 3: 302–307Czech J. Fo...

DURABLE EFFICACY OF DOLUTEGRAVIR (DTG) PLUS LAMIVUDINE (3TC) IN ANTIRETROVIRAL TREATMENT

DURABLE EFFICACY OF DOLUTEGRAVIR (DTG) PLUS LAMIVUDINE (3TC) IN ANTIRETROVIRAL TREATMENT

  • jasmine
  • 15 Slides

–. NAIVE ADULTS WITH HIV-1 INFECTION: 96-WEEK RE...

Jeanne Marrazzo, MD, MPH

Jeanne Marrazzo, MD, MPH

  • rose
  • 9 Slides

Professor of Medicine. University of Washington. S...

Cabotegravir, Long-acting Injectable

Cabotegravir, Long-acting Injectable

  • jacey
  • 34 Slides

Last Updated: October 6, 2023. Prepared by:. David...

HIV 2020: Time for change

HIV 2020: Time for change

  • garcia
  • 38 Slides

Dr. Kay Mahomed. Netcare. Garden City Clinic. Ma...

Retirement Plan Consulting

Retirement Plan Consulting

  • oconnor
  • 30 Slides

Overview of Services. Table of Contents. About RPA...

Optimization of Antiretroviral Therapy

Optimization of Antiretroviral Therapy

  • belinda
  • 26 Slides

With Emergence of Comorbidities. Roger J. . Bedimo...

EFV versus ATV + RTV, both with ABC-3TC or TDF-FTC

EFV versus ATV + RTV, both with ABC-3TC or TDF-FTC

  • felicity
  • 8 Slides

ACTG 5202. EFV versus ATV/r, both with ABC-3TC or ...

Switching from TDF/FTC to TAF/

Switching from TDF/FTC to TAF/

  • fanny
  • 6 Slides

FTC. Study 311-1089. Switching from TDF/FTC to TAF...

Switch from EFV plus ABC-3TC to EFV-TDF-FTC ROCKET-1 Trial

Switch from EFV plus ABC-3TC to EFV-TDF-FTC ROCKET-1 Trial

  • ricardo
  • 9 Slides

ROCKET-1 Trial. Switch from EFV + ABC-3TC to EFV-T...

Cases from the Clinic(ians): Case-based Panel Discussion

Cases from the Clinic(ians): Case-based Panel Discussion

  • tripp
  • 15 Slides

Associate Dean for Global Health. University of Al...

Raltegravir plus Ritonavir-Boosted Darunavir NEAT001/ANRS 143 Trial

Raltegravir plus Ritonavir-Boosted Darunavir NEAT001/ANRS 143 Trial

  • matthew167
  • 11 Slides

NEAT001/ANRS 143 Trial. Darunavir/r + Raltegravir ...

Update on risk factors, detection, and management of neuroc

Update on risk factors, detection, and management of neuroc

  • natalia-silvester
  • 61 Slides

Scott Letendre, M.D.. Professor of . Medicine and...

CDC’s Interim Guidance on the Use of PrEP in Heterosexual

CDC’s Interim Guidance on the Use of PrEP in Heterosexual

  • calandra-battersby
  • 81 Slides

Adults:. . Implications . for Clinical Practice....

COMING SOON:

COMING SOON:

  • luanne-stotts
  • 31 Slides

GENERIC ARVs. Tim Horn. Treatment Action Group. t...

TDF Microsoft Lync - Novembre 2010

TDF Microsoft Lync - Novembre 2010

  • faustina-dinatale
  • 9 Slides

Solutions & Architectures UC . Polycom. - Mi...

Highlights of AIDS

Highlights of AIDS

  • calandra-battersby
  • 44 Slides

2016: Advances in . HIV Prevention, Care and Trea...

COMPARATIVE INVESTIGATIONS ON NUTRITIONAL COMPOSITIONS OF O

COMPARATIVE INVESTIGATIONS ON NUTRITIONAL COMPOSITIONS OF O

  • lois-ondreau
  • 55 Slides

GROWN CEREALS AND THEIR RELATIONSHIPS. Dr. . Mirj...

PrEP Training for

PrEP Training for

  • tatyana-admore
  • 124 Slides

Providers in Clinical Settings. 2. Welcome!. Plea...

Treatment-Experienced Patients in Resource-Limited Settings

Treatment-Experienced Patients in Resource-Limited Settings

  • pasty-toler
  • 12 Slides

Susan M. Graham . Assistant Professor, Medicine a...

CROI 2015: What’s New in Hepatitis?

CROI 2015: What’s New in Hepatitis?

  • myesha-ticknor
  • 19 Slides

Nina Kim, MD . Associate Professor of Medicine. D...

Les satisfactions : traitements efficaces, robustes, avec u

Les satisfactions : traitements efficaces, robustes, avec u

  • phoebe-click
  • 23 Slides

Dr Denis Lacoste. Bordeaux. Les satisfactions : ....

ART Resistance and Second Line Regimens

ART Resistance and Second Line Regimens

  • calandra-battersby
  • 0 Slides

Learning Objectives. Understand when to switch to...

Review of Non-Daily PrEP Clinical Research and Experience

Review of Non-Daily PrEP Clinical Research and Experience

  • mitsue-stanley
  • 0 Slides

Robert M. Grant, M.D., M.P.H. .. IAS 2017, July 2...

ART for Prevention… What Happens Next?

ART for Prevention… What Happens Next?

  • briana-ranney
  • 0 Slides

Myron S. Cohen, MD. Yeargan-Bate Eminent Professo...

Adaptive non-inferiority

Adaptive non-inferiority

  • cheryl-pisano
  • 0 Slides

margins under observable non-constancy. Brett Han...

ART in Resource-limited settings :

ART in Resource-limited settings :

  • liane-varnes
  • 0 Slides

Progress and Challenges. Dr. B. B. . Rewari. MD,...

Generic treatments for HIV, HBV, HCV, TB could be mass produced for <$90 per patient

Generic treatments for HIV, HBV, HCV, TB could be mass produced for <$90 per patient

  • min-jolicoeur
  • 0 Slides

Dr Dzintars Gotham MBBS BSc(Hons). on behalf of. ...

Issues Affecting ART Success: Adherence, ARV Toxicity, Drug Interactions

Issues Affecting ART Success: Adherence, ARV Toxicity, Drug Interactions

  • pamella-moone
  • 0 Slides

Guidelines for the Use of Antiretroviral Agents i...

Comprehensive Guideline Summary

Comprehensive Guideline Summary

  • aaron
  • 0 Slides

Guidelines for the Use of Antiretroviral Agents. ...

Second-Generation HIV-1 Maturation Inhibitor BMS-955176: Antiviral Activity and Safety with Atazan

Second-Generation HIV-1 Maturation Inhibitor BMS-955176: Antiviral Activity and Safety with Atazan

  • sherrill-nordquist
  • 0 Slides

± . Ritonavir. Carey Hwang. ,. 1. Dirk Schürma...

Copyright © 2024 DocSlides. All Rights Reserved